Will GRECCAR 2 be a game changer for the management of rectal cancer?
- PMID: 32777139
- DOI: 10.1111/codi.15304
Will GRECCAR 2 be a game changer for the management of rectal cancer?
Comment on
-
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.Lancet Gastroenterol Hepatol. 2020 May;5(5):465-474. doi: 10.1016/S2468-1253(19)30410-8. Epub 2020 Feb 7. Lancet Gastroenterol Hepatol. 2020. PMID: 32043980 Clinical Trial.
References
-
- Rullier E, Vendrely V, Asselineau J et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol 2020; 5: 465-74.
-
- Lezoche E, Baldarelli M, Lezoche G et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg 2012; 99: 1211-8.
-
- Verseveld M, de Graaf EJR, Verhoef C et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 2015; 102: 853-60.
-
- Smart CJ, Korsgen S, Hill J et al. Multicentre study of short-course radiotherapy and transanal endoscopic microsurgery for early rectal cancer. Br J Surg 2016; 103: 1069-75.
-
- Montgomery v Lanarkshire Health Board [2015] SC 11 [2015] 1 AC 1430.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources